| Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir SJ Hadziyannis, V Sevastianos, I Rapti, D Vassilopoulos, E Hadziyannis Gastroenterology 143 (3), 629-636. e1, 2012 | 374 | 2012 |
| Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels EK Manesis, ES Hadziyannis, OP Angelopoulou, SJ Hadziyannis Antiviral therapy 12 (1), 73-82, 2007 | 218 | 2007 |
| Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection D Vassilopoulos, A Apostolopoulou, E Hadziyannis, GV Papatheodoridis, ... Annals of the rheumatic diseases 69 (7), 1352-1355, 2010 | 179 | 2010 |
| Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity E Tsochatzis, GV Papatheodoridis, E Hadziyannis, A Georgiou, G Kafiri, ... Scandinavian journal of gastroenterology 43 (9), 1128-1136, 2008 | 128 | 2008 |
| Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg‐negative chronic hepatitis B virus infection GV Papatheodoridis, N Chrysanthos, E Hadziyannis, E Cholongitas, ... Journal of viral hepatitis 15 (6), 434-441, 2008 | 119 | 2008 |
| Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B EK Manesis, GV Papatheodoridis, DG Tiniakos, ES Hadziyannis, ... Journal of hepatology 55 (1), 61-68, 2011 | 109 | 2011 |
| Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor … D Vassilopoulos, N Stamoulis, E Hadziyannis, AJ Archimandritis The Journal of Rheumatology 35 (7), 1271-1276, 2008 | 101 | 2008 |
| Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring EK Manesis, M Schina, F Le Gal, O Agelopoulou, C Papaioannou, ... Antiviral therapy 12 (3), 381-388, 2007 | 95 | 2007 |
| Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial GV Papatheodoridis, ES Hadziyannis, M Deutsch, SJ Hadziyannis Official journal of the American College of Gastroenterology| ACG 97 (8 …, 2002 | 92 | 2002 |
| DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B GV Papatheodoridis, EI Rigopoulou, M Papatheodoridi, K Zachou, ... Antiviral Therapy 23 (8), 677-685, 2018 | 83 | 2018 |
| Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor … D Vassilopoulos, S Tsikrika, C Hatzara, V Podia, A Kandili, N Stamoulis, ... Clinical and Vaccine Immunology 18 (12), 2102-2108, 2011 | 77 | 2011 |
| Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction M NEUMANN, J HARRISON, M SALTARELLI, E HADZIYANNIS, V ERFLE, ... AIDS research and human retroviruses 10 (11), 1531-1542, 1994 | 76 | 1994 |
| Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C E Tsochatzis, GV Papatheodoridis, V Koliaraki, E Hadziyannis, G Kafiri, ... Journal of viral hepatitis 17 (11), 800-806, 2010 | 75 | 2010 |
| Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy G Papatheodoridis, J Goulis, S Manolakopoulos, A Margariti, X Exarchos, ... Journal of Hepatology 60 (1), 62-68, 2014 | 73 | 2014 |
| Viral biomarkers in chronic HBeAg negative HBV infection E Hadziyannis, A Laras Genes 9 (10), 469, 2018 | 69 | 2018 |
| Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection GV Papatheodoridis, E Hadziyannis, E Tsochatzis, N Chrysanthos, ... Gut 57 (4), 500-506, 2008 | 68 | 2008 |
| Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease GV Papatheodoridis, E Hadziyannis, E Tsochatzis, A Georgiou, G Kafiri, ... Journal of Clinical Gastroenterology 44 (4), e87-e95, 2010 | 67 | 2010 |
| Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases C Hatzara, E Hadziyannis, A Kandili, C Koutsianas, A Makris, ... Annals of the rheumatic diseases 74 (10), 1848-1853, 2015 | 65 | 2015 |
| Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection I Mitroulis, C Hatzara, A Kandili, E Hadziyannis, D Vassilopoulos Annals of the rheumatic diseases 72 (2), 308-310, 2013 | 62 | 2013 |
| Circulating and liver tissue levels of retinol‐binding protein‐4 in non‐alcoholic fatty liver disease M Schina, J Koskinas, D Tiniakos, E Hadziyannis, S Savvas, ... Hepatology research 39 (10), 972-978, 2009 | 55 | 2009 |
